Literature DB >> 9761784

Membrane-bound calmodulin in Xenopus laevis oocytes as a novel binding site for melatonin.

M P Romero1, A García-Pergañeda, J M Guerrero, C Osuna.   

Abstract

Melatonin has been suggested as a physiological antagonist of calmodulin. In this work, we have characterized melatonin binding sites in Xenopus laevis oocyte membranes. Binding of [125I]melatonin by X. laevis oocyte membranes fulfills all criteria for binding to a receptor site. Binding was dependent on time, temperature, and membrane concentration and was stable, reversible, saturable, and specific. The binding site was also pharmacologically characterized. Stoichiometric studies showed a high-affinity binding site with a Kd of 1.18 nM. These data are in close agreement with data obtained from kinetic studies (Kd=0.12 nM). In competition studies, we observed a low-affinity binding site (Kd=63.41 microM). Moreover, the binding site was characterized as calmodulin. Thus, binding was dependent on calcium and blocked by anti-CaM antibodies in a concentration-dependent manner. Calmodulin inhibitor chlorpromazine also inhibited binding of the tracer. From these results, it is suggested that membrane-bound calmodulin acts as a melatonin binding site in Xenopus laevis oocytes, where it might couple cellular activities to rhythmic circulating levels of melatonin. This hypothesis correlates with the previous findings describing melatonin as a physiological antagonist of calmodulin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761784     DOI: 10.1096/fasebj.12.13.1401

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

Review 1.  Melatonin, clock genes and mitochondria in sepsis.

Authors:  Darío Acuña-Castroviejo; Ibtissem Rahim; Carlos Acuña-Fernández; Marisol Fernández-Ortiz; Jorge Solera-Marín; Ramy K A Sayed; María E Díaz-Casado; Iryna Rusanova; Luis C López; Germaine Escames
Journal:  Cell Mol Life Sci       Date:  2017-08-07       Impact factor: 9.261

Review 2.  Melatonin: A Cutaneous Perspective on its Production, Metabolism, and Functions.

Authors:  Andrzej T Slominski; Ruediger Hardeland; Michal A Zmijewski; Radomir M Slominski; Russel J Reiter; Ralf Paus
Journal:  J Invest Dermatol       Date:  2018-02-07       Impact factor: 8.551

3.  Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro.

Authors:  C L M Silva; E K Tamura; S M D Macedo; E Cecon; L Bueno-Alves; S H P Farsky; Z S Ferreira; R P Markus
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 4.  Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders.

Authors:  Adam Wichniak; Aleksander Kania; Mariusz Siemiński; Wiesław Jerzy Cubała
Journal:  Int J Mol Sci       Date:  2021-08-11       Impact factor: 5.923

Review 5.  Melatonergic drugs in development.

Authors:  Alessia Carocci; Alessia Catalano; Maria Stefania Sinicropi
Journal:  Clin Pharmacol       Date:  2014-09-18

Review 6.  Melatonin Target Proteins: Too Many or Not Enough?

Authors:  Lei Liu; Nedjma Labani; Erika Cecon; Ralf Jockers
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-15       Impact factor: 5.555

7.  MT3 melatonin binding site, MT1 and MT2 melatonin receptors are present in oocyte, but only MT1 is present in bovine blastocyst produced in vitro.

Authors:  Rafael V Sampaio; Stefanne Dhúllia B Conceição; Moysés S Miranda; Lucia de Fatima S Sampaio; Otávio Mitio Ohashi
Journal:  Reprod Biol Endocrinol       Date:  2012-12-03       Impact factor: 5.211

8.  New evidence for cross talk between melatonin and mitochondria mediated by a circadian-compatible interaction with nitric oxide.

Authors:  Paolo Sarti; Maria Chiara Magnifico; Fabio Altieri; Daniela Mastronicola; Marzia Arese
Journal:  Int J Mol Sci       Date:  2013-05-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.